Literature DB >> 18930441

Myelin basic protein-specific T lymphocytes proliferation and programmed cell death in demyelinating diseases.

Marina Saresella1, Ivana Marventano, Franca Rosa Guerini, Milena Zanzottera, Serena Delbue, Enrico Marchioni, Renato Maserati, Renato Longhi, Pasquale Ferrante, Mario Clerici.   

Abstract

A dynamic equilibrium between proliferation and programmed cell death (PCD) of auto-reactive T lymphocytes plays a pivotal role in the prevention of autoimmune diseases. We analyzed T lymphocytes myelin basic protein (MBP)-specific PCD and proliferation in demyelinating diseases. Results showed that MBP-specific PCD was significantly decreased in CD4+ and CD8+ T lymphocytes of progressive multifocal leukoencephalopathy (PML), not determined leukoencephalopathy (NDLE), and acute MS (AMS) patients compared to patients with stable MS (SMS) and healthy controls. MBP-specific proliferation/PCD rates were high in CD4+ T lymphocytes of PML, NDLE, and AMS patients, and in CD8+ T cells of PML and AMS individuals alone. Alterations of the balance between MBP-specific proliferation and PCD are present in demyelinating diseases and could play a major role in the pathogenesis of these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930441      PMCID: PMC2597154          DOI: 10.1016/j.clim.2008.08.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  24 in total

Review 1.  The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.

Authors:  R M Siegel; F K Chan; H J Chun; M J Lenardo
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

Review 2.  The machinery of programmed cell death.

Authors:  K C Zimmermann; C Bonzon; D R Green
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

Review 3.  Progressive multifocal leukoencephalopathy.

Authors:  J R Berger; E O Major
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

4.  Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.

Authors:  Amar Safdar; Ronald J Rubocki; Joseph A Horvath; Kailash K Narayan; Robert L Waldron
Journal:  Clin Infect Dis       Date:  2002-10-28       Impact factor: 9.079

5.  Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).

Authors:  Andrea Antinori; Antonella Cingolani; Patrizia Lorenzini; Maria Letizia Giancola; Ilaria Uccella; Simona Bossolasco; Susanna Grisetti; Francesca Moretti; Beniamino Vigo; Marco Bongiovanni; Bruno Del Grosso; Maria Irene Arcidiacono; Giovanni Carlo Fibbia; Maurizio Mena; Maria Grazia Finazzi; Giovanni Guaraldi; Adriana Ammassari; Antonella d'Arminio Monforte; Paola Cinque; Andrea De Luca
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy.

Authors:  T Dianne Langford; Scott L Letendre; Thomas D Marcotte; Ronald J Ellis; J Allen McCutchan; Igor Grant; Margaret E Mallory; Lawrence A Hansen; Sarah Archibald; Terry Jernigan; Eliezer Masliah
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

Review 7.  Control of apoptosis in autoimmunity.

Authors:  E Maniati; P Potter; N J Rogers; B J Morley
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

8.  Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy.

Authors:  Renaud A Du Pasquier; Marcelo J Kuroda; Joern E Schmitz; Yue Zheng; Kristi Martin; Fred W Peyerl; Michelle Lifton; Darci Gorgone; Patrick Autissier; Norman L Letvin; Igor J Koralnik
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  New insights into progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

10.  High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay.

Authors:  Michael P Crawford; Shirley X Yan; Sterling B Ortega; Riyaz S Mehta; Rachel E Hewitt; David A Price; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke; Nitin J Karandikar
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

View more
  5 in total

1.  Serum DNA motifs predict disease and clinical status in multiple sclerosis.

Authors:  Julia Beck; Howard B Urnovitz; Marina Saresella; Domenico Caputo; Mario Clerici; William M Mitchell; Ekkehard Schütz
Journal:  J Mol Diagn       Date:  2010-03-12       Impact factor: 5.568

2.  B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.

Authors:  Federica Piancone; Marina Saresella; Ivana Marventano; Francesca La Rosa; Martina Zoppis; Simone Agostini; Renato Longhi; Domenico Caputo; Laura Mendozzi; Marco Rovaris; Mario Clerici
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

3.  Aminooxyacetic acid improves learning and memory in a rat model of chronic alcoholism.

Authors:  Ai-Lin Du; Hao-Zhi Qin; Hong-Bo Jiang; Peng-Yan Fu; Ke Lou; Yu-Ming Xu
Journal:  Neural Regen Res       Date:  2018-09       Impact factor: 5.135

4.  Neuroinflammation and brain functional disconnection in Alzheimer's disease.

Authors:  Francesca Baglio; Marina Saresella; Maria Giulia Preti; Monia Cabinio; Ludovica Griffanti; Ivana Marventano; Federica Piancone; Elena Calabrese; Raffaello Nemni; Mario Clerici
Journal:  Front Aging Neurosci       Date:  2013-11-25       Impact factor: 5.750

5.  Determinants of disability in multiple sclerosis: an immunological and MRI study.

Authors:  Paola Tortorella; Maria Marcella Laganà; Marina Saresella; Eleonora Tavazzi; Maria Giulia Preti; Cristian Ricci; Francesca Baglio; Ivana Marventano; Federica Piancone; Giuseppe Baselli; Pietro Cecconi; Domenico Caputo; Mario Clerici; Marco Rovaris
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.